Summary
Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone®; dihydroxyanthracenedione) was administered in a dose of 8–13 mg/m2 on five consecutive days. Five of 20 evaluable patients were induced into complete remission, one patient achieved a partial remission. Side-effects included moderate to severe bone marrow suppression, moderate mucositis and hair loss. No cardiotoxicity was observed. We believe that mitoxantrone is an active agent in the treatment of acute leukemia and suggest further studies in combination chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cheng CC, Zbinden G, Zee-Cheng RK-Y: Comparison of antineoplastic activity of aminoethyl-amino-anthraquinones and anthracycline antibiotics. J Pharm Sci 68: 393–396, 1979
Double JC, Brown JR: Evaluation of binding of some substituted anthraquinones and anthracycline antibiotics. J Pharm Pharmacol 28:166–169, 1976
Johnson RK, Zee-Chung RK-Y, Lee WW, Acton EM, Henry DW, Cheng CC: Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63:425–439, 1979
Wallace RE, Murdock KC, Angier RB, Durr FE: Activity of a novel anthracenedione, 1, 4-dihydroxy-5, 8-bis-[[2[(2- hydroxyethyl)amino)ethyl)amino]-9, 10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:291–294, 1978
Smith IE, Stuart-Harris R, Pavladis N, Bozek T: Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 10 (Suppl B):37–40, 1983
Coltman CA Jr, Saiki JH, Panettiere FJ, Balcerzak SP, Stephens RL, Morrison FS, Dixon DO, Von Hoff DD: Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group phase II studies. In M Rozencweig, DD Von Hoff and MJ Staquet (eds.): New Anticancer Drugs: Mitoxantrone and Bisantrene. Raven Press, New York, 1983, pp 115–124
Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43:3919–3922, 1983
Arlin Z, Silver R, Cassileth P, Armentrout S, Gams R, Erslev A, Amare M, Broun G, Schoch I, Dukhart G: Phase I–II trial of mitoxantrone in adult acute leukemia (Abstract 6–15). 2nd European Conference on Clinical Oncology and Cancer Nursing, Amsterdam, 1983
Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10 (Suppl B):57–63, 1983
Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ: Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67:390–391, 1983
Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF: Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66:1139–1143, 1982
Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF: Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 66:1145–1158, 1982
World Health Organization: WHO handbook for reporting results of cancer treatment, WHO, Geneva, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meyer, P., Ho, A.D., Ehninger, G. et al. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 3, 203–206 (1985). https://doi.org/10.1007/BF00174171
Issue Date:
DOI: https://doi.org/10.1007/BF00174171